Switzerland Begins Reviewing COVID-19 Vaccine Candidate From the USA

The US-based biotech company Moderna has submitted an application to Swissmedic, the Swiss Agency for Therapeutic Products, for the authorization of mRNA-1273, an experimental vaccine candidate, targeted against the novel SARS-CoV-2 coronavirus.

'The rolling submission procedure for mRNA-1273 is based on the initially submitted data packages on the preclinical situation and quality, as well as on preliminary clinical data. In a rolling review, the data can be evaluated as soon as they become available. The companies can then submit the latest data continuously without having to wait for the conclusive results from all studies,' stated the Swissmedic press statement issued on November 13, 2020.